Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TREM-1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TREM-1 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. |
View TREM1 Products |
| Gene Delivery | TREM-1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based functional assays. |
View TREM1 Products |
| Benchmark Ab | Anti-TREM-1 Recombinant Antibody (Sequence of UTTR1147A/RG6183) Recombinant positive control for benchmarking binding and blocking assays. |
View TREM1 Products |
| Validator | TREM-1 siRNA Set For target knockdown verification and target specificity validation in primary myeloid cells. |
View TREM1 Products |
| Related Target A | TREM-2 (Triggering Receptor Expressed on Myeloid Cells 2) Crucial counter-screening target. High homology with TREM-1; selectivity is vital to avoid off-target effects. |
View TREM2 Products |
| Related Target B | TLR4 (Toll-Like Receptor 4) Synergistic pathway partner. TREM-1 amplifies TLR4-mediated inflammatory cascades. |
View TLR4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus TREM-1 ortholog proteins available with >95% purity by SDS-PAGE. |
| Subfamily counter-screening (TREM-2/TREML) | Homolog panel proteins strictly verified by mass spectrometry and sequence analysis to guarantee zero cross-contamination. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included to validate assay sensitivity and dynamic range. |
| False Positives | Validated siRNA included for specificity checks in primary human monocytes and neutrophils. |
Live TREM-1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TREM-1 therapeutics is intensifying, with major players shifting focus from traditional systemic anti-inflammatory mAbs to tissue-targeted approaches and immuno-oncology applications. As first-generation therapies targeting inflammatory bowel disease (IBD) and acute pancreatitis reach advanced clinical phases, the next wave of R&D is targeting the myeloid-derived suppressor cell (MDSC) microenvironment in solid tumors. Modulating TREM-1 offers a powerful lever to reprogram immunosuppressive macrophages, making it a highly sought-after target for combination therapies with PD-(L)1 inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antagonistic mAb | Roche (Genentech), Innate Pharma | Inflammatory Bowel Disease (IBD), Sepsis | Blocking Assay & sTREM-1 Decoy Competition (Need high-purity ECD-Fc) |
| Agonistic/Blocking mAb | Incyte, Pionyr Immunotherapeutics | Solid Tumors (Immuno-Oncology) | Myeloid Cell Activation/Reprogramming (Need Lentivirus for Stable Cell Lines) |
| Small Molecule inhibitors | SignaBlok, Academic Institutions | Acute Lung Injury, Rheumatoid Arthritis | High-throughput screening and selectivity assays (Need Mutant vs WT Proteins) |